Cell Line Development Market 2012 - 2022 Size, Growth & Forecast Analysis Report

29/dic/2020 07:00:29 Grand View Research Contatta l'autore

Questo comunicato è stato pubblicato più di 30 giorni fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global cell line development market size is expected to reach USD 6.24 billion by 2022, according to a new report by Grand View Research, Inc. The Increasing demand for monoclonal antibodies and patent expiration of blockbuster biologics are expected to drive the cell line development industry over the forecast period.

Increasing prevalence of autoimmune diseases and cancer is likely to increase the demand for accurate and cost-effective treatment options which is expected to render a positive impact on market growth. In addition, improving healthcare infrastructure, economic development and favorable government initiatives promoting the growth of the biotechnology industry are factors contributing towards the growth of the cell line development market.

Ongoing R&D for stable & authentic cell lines and the introduction of technologically advanced processes such as single-use bioreactor and microbioreactor for large scale bioproduction are further expected to provide this market with lucrative future growth opportunities.

Further key findings from the study suggest:

·         Reagent and media was the largest product market in 2014, owing to the increasing number of cell culture procedures. Reagent and media are necessary components involved in cell line development procedures & cell culture and are cost-intensive in nature. The market for reagent and media was valued at over 1.0 billion in 2014.

·         Mammalian cell lines were widely used as a source for cell line development in 2014, owing to associated advantages such as accurate complex protein expression nature, critical for the production of monoclonal antibodies, vaccines, and biologics.

·         Cell line development finds the largest application in the bioproduction of biologics, vaccines, Mabs, therapeutic proteins, and biosimilars. Rising demand for monoclonal antibodies and vaccines are expected to boost the growth of this segment over the forecast period. The market for cell line development based bioproduction is also expected to witness lucrative growth of over 12.5% during the forecast period.

·         North America was the largest market in 2014, with revenue estimated at over 800 million. The region’s market dominance is attributed to factors such as the growing adoption rates of cell culture techniques, the presence of well-developed healthcare infrastructure, supportive government initiatives and high healthcare expenditure levels.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/cell-line-development-market

·         Asia Pacific cell line development market is anticipated to register rapid growth over the forecast period owing to factors such as the presence of high unmet needs, rising number of CROs (Contract Research Organization) providing pertinent services, growing R&D investments aimed at the development of stable cell lines and increasing biologics production.

·         Key players in this market include European Collection of Cell Cultures (ECACC), Lonza Group AG, GE Healthcare, Thermo Fisher Scientific Inc., Sartorius AG, Selexis SA, Wuxi AppTec Inc., Sigma-Aldrich Corporation, American Type Culture Collection (ATCC) and Corning Inc.

Grand View Research has segmented the global cell line development market on the basis of product, source, type of cell line, application, and region:

Global Cell Line Development Product Outlook (Revenue, USD Million, 2012 - 2022)

o    Reagents and media

o    Equipment Accessories and consumables

o    Incubators

o    Centrifuges

o    Bioreactors

o    Storage equipment

o    Microscopes

Global Cell Line Development Source Outlook (Revenue, USD Million, 2012 - 2022)

o    Mammalian

o    Non mammalian

o    Insects

o    Amphibians

Global Cell Line Development Type Of Cell Line Outlook (Revenue, USD Million, 2012 - 2022)

o    Recombinant cell lines

o    Hybridomas

o    Continuous cell line

o    Primary cell lines

blog comments powered by Disqus
Comunicati.net è un servizio offerto da Factotum Srl